{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:21:30Z","timestamp":1767651690323},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,5,4]],"date-time":"2007-05-04T00:00:00Z","timestamp":1178236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2007,8,23]]},"DOI":"10.1007\/s10875-007-9096-9","type":"journal-article","created":{"date-parts":[[2007,5,3]],"date-time":"2007-05-03T18:25:12Z","timestamp":1178216712000},"page":"503-509","source":"Crossref","is-referenced-by-count":21,"title":["Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases"],"prefix":"10.1007","volume":"27","author":[{"given":"Melvin","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco A","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Othmar","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Ballow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,4]]},"reference":[{"key":"9096_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","volume":"94","author":"FA Bonilla","year":"2005","unstructured":"Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU: Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94:S1\u2013S63, 2005 (available at: http:\/\/www.jcaai.org\/pp\/pp-immunodeficiency-update_05-0602.pdf)","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9096_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/bmj.308.6928.581","volume":"308","author":"HM Chapel","year":"1994","unstructured":"Chapel HM: Consensus on diagnosis and management of primary antibody deficiencies. Consensus panel for the diagnosis and management of primary antibody deficiencies. BMJ 308:581\u2013585, 1994","journal-title":"BMJ"},{"issue":"suppl 4","key":"9096_CR3","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C: Primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology: Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(suppl 4):S525\u2013553, 2006","journal-title":"J Allergy Clin Immunol"},{"key":"9096_CR4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","volume":"1","author":"CM Roifman","year":"1987","unstructured":"Roifman CM, Levison H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1:1075\u20131077, 1987","journal-title":"Lancet"},{"key":"9096_CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000083948","volume":"136","author":"A Durandy","year":"2005","unstructured":"Durandy A, Wahn V, Petteway S, Gelfand E: Immunoglobulin replacement therapy in primary antibody deficiency diseases\u2014maximizing success. Int Arch Allergy Immunol 136:217\u2013229, 2005","journal-title":"Int Arch Allergy Immunol"},{"key":"9096_CR6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.intimp.2005.11.003","volume":"6","author":"EW Gelfand","year":"2006","unstructured":"Gelfand EW: Differences between IGIV products: Impact on clinical outcome. Int Immunopharmacol 6:592\u2013599, 2006","journal-title":"Int Immunopharmacol"},{"key":"9096_CR7","first-page":"60","volume":"19","author":"JS Epstein","year":"2000","unstructured":"Epstein JS, Zoon KC: Important drug warning: Immune globulin intravenous (human) (IGIV) products. Neonatal Netw 19:60\u201362, 2000","journal-title":"Neonatal Netw"},{"key":"9096_CR8","first-page":"518","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","unstructured":"Centers for Disease Control and Prevention (CDC): Renal insufficiency and failure associated with immune globulin intravenous therapy\u2014United States, 1985\u20131998. MMWR Morb Mortal Wkly Rep 48:518\u2013521, 1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9096_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","volume":"17","author":"LR Pierce","year":"2003","unstructured":"Pierce LR, Jain N: Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17:241\u2013251, 2003","journal-title":"Transfus Med Rev"},{"key":"9096_CR10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000079071","volume":"31","author":"M Borte","year":"2004","unstructured":"Borte M, Davies SV, Touraine J-L, Farber C-M, Lipsic T, Adams C, Spath P, Bolli R, Morell A, Andresen I: Clinical properties of a novel liquid intravenous immunoglobulin: Studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Transfus Med Hemother 31:126\u2013134, 2004","journal-title":"Transfus Med Hemother"},{"key":"9096_CR11","unstructured":"Andresen I, Schmugge M, Ridolfi-L\u00fcthi A, Adams C, Bender K: An open label, multi center study in pediatric acute idiopathic thrombocytopenic purpura. Presented at the European Hematology Association Annual Congress, Lyon, 2003. Abstract number 0763 (http:\/\/eurocongres.com\/eha2003\/eha_scientific.html)"},{"key":"9096_CR12","unstructured":"FDA: Draft guidance for industry. Safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. http:\/\/www.fda.gov\/CBER\/gdlns\/igivimmuno.pdf"},{"key":"9096_CR13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","volume":"3","author":"CM Roifman","year":"2003","unstructured":"Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G: Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 3:1325\u20131333, 2003","journal-title":"Int Immunopharmacol"},{"key":"9096_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1423-0410.2006.00764.x","volume":"90","author":"J Bjorkander","year":"2006","unstructured":"Bjorkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ: Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 90:286\u2013293, 2006","journal-title":"Vox Sang"},{"key":"9096_CR15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","volume":"26","author":"JA Church","year":"2006","unstructured":"Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, Wasserman RL, Pavlova BG, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich HJ: US-PID-IGIV 10%-Study Group 10: Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 26:388\u2013395, 2006","journal-title":"J Clin Immunol"},{"key":"9096_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"HD Ochs","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M: Subcutaneous IgG Study Group: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26:265\u2013273, 2006","journal-title":"J Clin Immunol"},{"key":"9096_CR17","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.jaci.2005.12.440","volume":"117","author":"EA Cassidy","year":"2006","unstructured":"Cassidy EA, Pinciaro PJ, Berger M: For the Grifols 0404-OLEIG201 investigators: Antibody deficiency in the new millennium: Illnesses, absences, and concomitant medications\u2014100 patient years\u2019 experience. J Allergy Clin Immunol 117:S110, 2006","journal-title":"J Allergy Clin Immunol"},{"key":"9096_CR18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","volume":"24","author":"M Berger","year":"2004","unstructured":"Berger M, Pinciaro PJ: Flebogamma 5% investigators: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389\u2013396, 2004","journal-title":"J Clin Immunol"},{"key":"9096_CR19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","volume":"135","author":"HW Eijkhout","year":"2001","unstructured":"Eijkhout HW, Van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: Inter-University Working Party for the Study of Immune Deficiencies: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165\u2013174, 2001","journal-title":"Ann Intern Med"},{"key":"9096_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","volume":"21","author":"UE Nydegger","year":"1999","unstructured":"Nydegger UE, Sturzenegger M: Adverse effects of intravenous immunoglobulin therapy. Drug Safety 21:171\u2013185, 1999","journal-title":"Drug Safety"},{"key":"9096_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","volume":"136","author":"R Ameratunga","year":"2004","unstructured":"Ameratunga R, Sinclair J, Kolbe J: Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 136:111\u2013113, 2004","journal-title":"Clin Exp Immunol"},{"key":"9096_CR22","unstructured":"Work Loss Data Institute: Official disability guidelines. 6\/17\/02. Available at: http:\/\/www.disabilitydurations.com\/pr_repmdc.htm, 2002"},{"key":"9096_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2003.08.004","volume":"32","author":"L Gregori","year":"2004","unstructured":"Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG: Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32:1\u201310, 2004","journal-title":"Biologicals"},{"key":"9096_CR24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.intimp.2005.11.004","volume":"6","author":"J Siegel","year":"2006","unstructured":"Siegel J: Safety considerations in IGIV utilization. Int Immunopharmacol 6:523\u2013527, 2006","journal-title":"Int Immunopharmacol"},{"key":"9096_CR25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2146\/ajhp050282","volume":"62","author":"S Shah","year":"2005","unstructured":"Shah S: Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 62:S5\u201311, 2005","journal-title":"Am J Health Syst Pharm"},{"key":"9096_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y: Intravenous immunoglobulin: Adverse effects and safe administration. Clin Rev Allergy Immunol 29:173\u2013184, 2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"9096_CR27","unstructured":"Berger M: Use of IGIV in Primary Immune Deficiency. Parts I and II. In UpToDate, Steihm ER, 2004. Updated, 2006"},{"key":"9096_CR28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biologicals.2003.09.001","volume":"31","author":"M Kroez","year":"2003","unstructured":"Kroez M, Kanzy EJ, Gronski P, Dickneite G: Hypotension with intravenous immunoglobulin therapy: Importance of pH and dimer formation. Biologicals 31:277\u2013286, 2003","journal-title":"Biologicals"},{"key":"9096_CR29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood.V95.5.1856.005k03_1856_1861","volume":"95","author":"WK Bleeker","year":"2000","unstructured":"Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, Tool AT, Koenderman AH, Kuijpers TW, Hack CE: Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95:1856\u20131861, 2000","journal-title":"Blood"},{"issue":"suppl","key":"9096_CR30","first-page":"96","volume":"96","author":"MO Spycher","year":"1999","unstructured":"Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Sp\u00e4th P, Schnorf J: Well-tolerated liquid intravenous immunoglobulin G preparations (IGIVs) have a low immunoglobulin G dimer content. J Autoimmunity 96(suppl):96 (abstract), 1999","journal-title":"J Autoimmunity"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-007-9096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-007-9096-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-007-9096-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T18:30:14Z","timestamp":1587493814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-007-9096-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,8,23]]}},"alternative-id":["9096"],"URL":"https:\/\/doi.org\/10.1007\/s10875-007-9096-9","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,4]]}}}